Recent events
Recent events tied to this brand in public sources.
Back to profile7 entries
2026
CSL expects to complete U.S. rollout of Haemonetics plasmapheresis platform by end of 2027
CSL expects to complete the rollout of Haemonetics' plasmapheresis platform across the United States by the end of 2027. Haemonetics shares popped 8% in premarket trading on the news.
2021
Haemonetics agrees to acquire Cardiva Medical
Haemonetics said it had agreed to acquire Cardiva Medical for $475 million in cash upfront; the deal was expected to close in the first quarter of 2021.
2020
Haemonetics announced sale of Puerto Rico manufacturing operations to GVS
Haemonetics announced a definitive agreement to sell its Fajardo, Puerto Rico manufacturing operations to GVS. The proposed transaction includes certain operating assets; Haemonetics would retain the intellectual property rights to its proprietary blood filters.
2020
Haemonetics and GVS announced planned blood-filter supply and development collaboration
Haemonetics and GVS announced that, in connection with the proposed sale, they will enter into a long-term supply and development agreement. The agreement is to grant GVS exclusive rights to manufacture and supply the blood filters currently produced at Haemonetics' Fajardo facility for Haemonetics.
2020
Haemonetics agrees to sell blood donor software assets to GPI
Haemonetics announced a definitive agreement to sell certain blood donor management software solution assets to the GPI Group. The transaction was expected to close in the second quarter of 2020, subject to customary closing conditions.
2020
Haemonetics acquires enicor GmbH
Haemonetics announced that it had acquired all of the outstanding share capital of enicor GmbH, a Munich-based manufacturer of the ClotPro whole-blood coagulation testing system.
2020
Haemonetics acquires TEG 6s intellectual property
Haemonetics announced that it purchased the technology underlying the TEG 6s Hemostasis Analyzer System from CoraMed Technologies and acquired ownership of related intellectual property.